Acro Biomedical Co., Ltd.
ACBM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $6 | $270 | $250 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $6 | $270 | $250 |
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | – | -100% | -45% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 21.3% | 21.7% |
| EBITDA | -$0 | $0 | -$16 | $0 |
| % Margin | – | – | -2,410% | 0% |
| Net Income | -$0 | -$9 | -$16 | -$8 |
| % Margin | – | – | -2,410.2% | -643.2% |
| EPS Diluted | -0.001 | -0.15 | -0.26 | -0.14 |
| % Growth | 99.5% | 42.3% | -85.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |